Last Updated February 1, 2024

 February 1, 2024

Determining the correct semaglutide dosage is incredibly important for achieving transformative weight loss and improving overall health.

When researching how to lose excess weight, manage diabetes, or maintain cardiovascular well-being, it's crucial to understand semaglutide dosing.

Semaglutide has demonstrated numerous benefits in clinical trials, including:

  • Weight loss
  • Diabetes management
  • Cardioprotective effects
  • Improved overall metabolic health

Its remarkable ability to induce significant weight loss has generated considerable interest among medical experts and individuals struggling with weight-related issues.

This educational review aims to examine semaglutide and its recommended dosages for a number of uses. Read through the end, where we provide weight loss researchers with our top recommendation on where to source top-quality semaglutide online.

Buy Semaglutide from our top-rated vendor...

Disclaimer: contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Likewise, any published information relative to the dosing and administration of reference materials is made available strictly for reference and shall not be construed to encourage the self-administration or any human use of said reference materials. makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.

Semaglutide Dosage Chart | Quick Breakdown

Timeline Weeks
17- (full dose)
Semaglutide Weight Loss Dose [1x weekly] 0.25mg 0.5mg 1mg 1.7mg 2.4mg

What is Semaglutide?

Semaglutide is a medication that belongs to the class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1-RA). It is used for the treatment of type 2 diabetes mellitus, weight management, and cardiovascular risk [1].

Semaglutide works by mimicking the action of the natural incretin hormone glucagon-like peptide-1 (GLP-1), which is responsible for regulating blood sugar levels [2].

By activating GLP-1 receptors, semaglutide stimulates insulin secretion, reduces the production of glucagon (a hormone that raises blood sugar levels), slows down stomach emptying, and promotes feelings of fullness [2].

In treating type 2 diabetes, semaglutide helps lower blood sugar levels, improve glycemic control, and reduce the risk of cardiovascular events in patients with established cardiovascular disease [3].

In addition to its anti-diabetic effects, semaglutide has also been approved for chronic weight management in adults with obesity or overweight. In late 2022, the FDA also approved semaglutide for the treatment of obesity in pediatric patients aged 12 and older [4].

Semaglutide helps to promote weight loss by reducing appetite, increasing satiety, and supporting overall weight management efforts. The recommended total weekly dose for this indication is 2.4mg, in addition to following a reduced-calorie meal plan and engaging in increased physical activity [4].

Semaglutide is offered in subcutaneous and oral tablet forms. The dosage and administration of subcutaneous semaglutide may differ based on the indication and individual considerations, while the oral form is exclusively approved for diabetes.

semaglutide dosage calculator

Recommended Dosage for Semaglutide

In this section, we set out established semaglutide dosing schedules based on the research objective.

Semaglutide Dose for Weight Loss

The typical adult dosage for weight loss is based on the Wegovy (brand name semaglutide) prescribing guidelines at time of writing. Weeks 1-16 follow an initial dose escalation schedule, while the full dose is reached at week 17 of administration, as follows [5]:

  • Weeks 1-4: 0.25mg subcutaneously once weekly.
  • Weeks 5-8: 0.5mg subcutaneously once weekly.
  • Weeks 9-12: 1mg subcutaneously once weekly.
  • Weeks 13-16: 1.7mg subcutaneously once weekly.
  • Weeks 17 & beyond: 2.4mg subcutaneously once weekly.

Semaglutide Dose for T2D Management

The typical adult dosage of semaglutide for the treatment of type 2 diabetes is also drawn from the Wegovy prescribing guidelines, but involves significantly lower dosing [5]:

  • Initial Dose: Administer 0.25mg subcutaneously once weekly for 4 weeks, then increase to 0.5mg subcutaneously once weekly.
  • Titration: In the event that further regulation of glycemic levels is required following a minimum of four weeks at the 0.5mg dosage, consider escalating the dose to 1mg weekly.
  • Maintenance Dose: The recommended maintenance dose is between 0.5mg and 1mg/weekly.
  • Maximum Dose: The maximum recommended dose is 1mg once weekly.

The typical adult dosage for T2D with semaglutide oral tablets is based on the Rybelsus prescribing guidelines and involves significantly higher dosing, due to the reduced bioavailability of semaglutide oral [6]:

  • Initial Dose: 3mg orally once daily for 30 days, then increase to 7mg orally once daily.
  • Titration: If further glycemic control is required after at least 30 days on 7mg/daily, the dose may be increased to 14mg orally once daily.
  • Maintenance Dose: The recommended maintenance dose is between 7mg and 14mg orally, once daily.
  • Maximum Dose: The maximum recommended dose is 14mg/day.

When switching a research subject between subcutaneous semaglutide and oral tablets, consider the following guidelines [5, 6]:

  • From oral to subcutaneous: Subjects on 14mg orally once daily may transition to 0.5mg subcutaneously once weekly. Subcutaneous administration should start after the last oral dose.
  • From subcutaneous to oral: Subjects receiving 0.5mg subcutaneously once weekly can switch to 7mg or 14mg orally once daily. Oral therapy should begin up to seven days after.

Semaglutide Dose for Cardiovascular Risk

The typical adult dosage for cardiovascular risk reduction is determined based on the specific oral or subcutaneous medication prescribed. Below, we present the typical adult dosages for cardiovascular risk reduction.

Subcutaneous Administration [5]:

  • Initial Dose: Administer 0.25mg subcutaneously once weekly for four weeks, then increase to 0.5mg subcutaneously once weekly.
  • Titration: In the event that further glycemic control is required following a minimum of four weeks at the 0.5mg dosage, consider escalating the dose to 1mg administered subcutaneously on a weekly basis.
  • Maintenance Dose: The recommended maintenance dose is between 0.5mg and 1mg subcutaneously once weekly.
  • Maximum Dose: The maximum recommended dose is 1mg/weekly.

Oral Tablets [6]:

  • Initial Dose: 3mg orally once daily for 30 days, then increase to 7mg orally once daily.
  • Titration: If further glycemic control is required after at least 30 days on 7mg/day, the dose may be increased to 1 mg orally once daily.
  • Maintenance Dose: The recommended maintenance dose is between 7mg and 14mg orally once daily.
  • Maximum Dose: The maximum recommended dose is 14mg/day.

When administering semaglutide to research subjects, it is important to consider dose adjustments and take necessary precautions [5, 6]:

  • Renal Dose Adjustments: No dosage adjustment is recommended for subjects with renal impairment.
  • Liver Dose Adjustments: No dosage adjustment is necessary for subjects with liver impairment.
  • Dose Adjustments: When semaglutide is combined with an insulin secretagogue (such as a sulfonylurea) or insulin, there is an increased risk of hypoglycemia, including severe hypoglycemia. It may be necessary to reduce the insulin secretagogue or insulin dose to minimize the risk of hypoglycemia.

Semaglutide Dosage Calculator

In this section, we cover the two primary methods of administering semaglutide, which are subcutaneous and orally via tablets. We explore the characteristics, benefits, and considerations associated with each form of administration.

Subcutaneous Semaglutide

The dosage of subcutaneous semaglutide varies depending on the specific condition being treated (refer to the above dosage charts).

The recommended dosing regimen for semaglutide for weight reduction entails initiating treatment with a 0.25mg dose once weekly for the initial four weeks. Following that, the dose is progressively escalated at four-week intervals until reaching a maintenance dose of 2.4mg once weekly [5].

Dosing may be adjusted based on the individual subject’s needs and tolerability.

Semaglutide Oral Tablets

Semaglutide oral tablets are currently approved strictly for treating diabetes and are available in different strengths. The usual starting dose is 3mg once daily for 30 days.

After 30 days, the dosage is increased to 7mg once daily. It's important to follow the specific instructions provided or outlined in the product labeling [6].

Benefits of Semaglutide

In this section, we will provide an overview of the benefits of semaglutide, a drug that has demonstrated safety and effectiveness in a range of indications. We will explore its use in weight loss, diabetes management, and cardiovascular health.

Semaglutide for Type 2 Diabetes

Extensive phase 3 clinical testing has been conducted on both the subcutaneous and oral formulations of semaglutide. The once weekly subcutaneous formulation underwent evaluation in the SUSTAIN program (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes), which comprised 13 distinct randomized clinical phase 3a and 3b trials [7].

The SUSTAIN trials encompassed global international studies (SUSTAIN 1 through 10), with three additional trials dedicated to China and Japan [7].

Semaglutide is beneficial as a treatment option for type 2 diabetes:

  • Lower Blood Sugar Levels: Semaglutide helps regulate blood sugar levels by increasing insulin secretion and reducing glucagon production, leading to improved glycemic control [7].
  • Reduced Risk of Cardiovascular Disease: Studies have shown that semaglutide not only helps manage diabetes but also reduces the risk of major adverse cardiovascular events such as cardiovascular death, non-fatal myocardial infarction, or nonfatal stroke in patients with established cardiovascular disease [8].

Semaglutide for Weight Loss

Semaglutide has been found to be effective in promoting weight loss in overweight and obesity. The following benefits contribute to its weight loss effects:

  • Reduced Appetite and Food Cravings: Semaglutide acts on the brain's appetite control centers, leading to decreased cravings for high-calorie foods and appetite overall [3].
  • Increased Satiety and Fullness: By slowing down the emptying of the stomach and promoting feelings of fullness, semaglutide helps subjects eat less and avoid overeating [3].
  • Lower Body Weight and BMI: Clinical trials have demonstrated significant weight loss among volunteers receiving semaglutide treatment. The reduction in body weight also corresponds to improvements in metabolic parameters such as waist circumference and body mass index (BMI) [8].

Other Potential Semaglutide Benefits

Apart from its primary indications, semaglutide shows potential benefits in other areas:

  • Cardiovascular Benefits in Non-diabetics: Semaglutide has demonstrated favorable effects on cardiovascular outcomes in subjects with or without diabetes, indicating its potential for cardiovascular risk reduction in a broader population [9].
  • Non-Alcoholic Steatohepatitis (NASH): Research suggests that semaglutide may have a positive impact on non-alcoholic steatohepatitis, a liver disease associated with metabolic syndrome and obesity [9].
  • Renal Benefits: Preliminary studies indicate that semaglutide may have renal benefits, including a potential reduction in albuminuria and preservation of kidney function, although further research is needed to establish its efficacy.

Semaglutide Side Effects and Safety

Although the primary objective of GLP-1RA therapy is to reduce blood glucose levels, there is a potential risk of hypoglycemia associated with agents like semaglutide.

Notably, the occurrence of hypoglycemia is generally low due to the glucose-dependent insulin secretion stimulated by GLP-1RA. This mechanism ensures that insulin is released in response to elevated blood glucose levels, reducing the likelihood of hypoglycemic events. [7, 9].

Additionally, it is important to note that the inhibition of glucagon release does not occur during hypoglycemic conditions. Therefore, when using subcutaneous and oral semaglutide alone, the risk of hypoglycemia is minimal [10].

Mild to moderate side effects such as nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite are commonly associated with the use of semaglutide and liraglutide [10].

In most cases, these side effects tend to diminish as the body adjusts to the medication.

Serious Side Effects

While uncommon, it is important to be aware that semaglutide may have serious side effects that demand prompt medical attention. These can include significant gastrointestinal complications like pancreatitis (inflammation of the pancreas) and issues with the gallbladder [11].

Signs of pancreatitis may manifest as intense abdominal pain, accompanied by nausea and vomiting [12].

Additionally, other severe side effects can encompass allergic reactions, thyroid tumors, hypoglycemia (low blood sugar), and kidney problems [13].

Safety Considerations and Contraindications

When used under the supervision of qualified professionals, semaglutide is generally considered safe. However, it is important to be aware of certain safety considerations:

  • Semaglutide should not be administered to subjects with a personal or family history of medullary thyroid carcinoma, a form of thyroid cancer [14].
  • Additionally, it should not be used in subjects with multiple endocrine neoplasia syndrome type 2, a genetic disorder associated with thyroid cancer [15].
  • Semaglutide should not be used in subjects who have previously experienced a serious hypersensitivity reaction to semaglutide or any of its components. It is also contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [16].
  • Regarding patients undergoing dialysis, no specific dosage adjustment is recommended. However, it is important to exercise caution when using semaglutide in this population due to limited available data [16].

semaglutide dosage calculator

Where to Buy Semaglutide Online? | 2024 Edition

When it comes to conducting research with semaglutide, we highly recommend buying a research-grade version of this peptide from either of the two following vendors.

Limitless Life

Limitless Life is a US-based vendor that offers semaglutide through its member’s only VIP club.

Here's why they are the ideal choice for acquiring semaglutide:

  • Semaglutide Made in the USA: This vendor manufactures semaglutide in the USA, adhering to strict quality standards and regulatory guidelines. By choosing semaglutide from Limitless Life, researchers can have confidence in the production process.
  • Comprehensive Information: Limitless Life provides detailed and comprehensive information about semaglutide, including its mechanisms of action and potential research applications.
  • Free Delivery on $350+ Orders: Limitless Life offers the benefit of free domestic delivery on orders totaling $350+ or more, providing a cost-saving advantage.
  • Fantastic Service and Support: The vendor’s professional support staff is available during normal business hours by phone and email to answer any question about products or orders.

Click the link below to join Limitless Life’s VIP Club and get exclusive access to their semaglutide products. Sign up is simple and instant:

Buy Semaglutide from our top-rated vendor...

Research Chemical

Research Chemical is another preferred choice for researchers seeking a reliable and convenient source of semaglutide.

Here’s why we trust them:

  • Lab-Tested Peptides: Research Chemical guarantees the quality of their semaglutide through rigorous lab testing, ensuring high levels of purity.
  • Attractive Prices: Semaglutide 5mg from Research Chemical currently retails for $150, which represents good value for the sought-after compound.
  • Exceptional Service Team: Satisfaction of researchers is a top priority at Research Chemical. Their excellent service team ensures a positive and fulfilling experience throughout the purchasing journey.

Researchers can now get 15% off the next order by entering promo code “peptides15” at checkout with Research Chemical.

Buy research peptides from Research Chemical today...

Bacteriostatic Water for Semaglutide

When exploring the properties and benefits of semaglutide, the lab will need to obtain bacteriostatic water and ancillary supplies for research.

Choose this vendor as a trusted supplier of bacteriostatic water and other laboratory supplies. Here's why they are the perfect match for research endeavors:

  • Unparalleled Commitment to Quality: They uphold the highest standards of quality for their research supplies.
  • Preserving Semaglutide Stability: Bacteriostatic water is infused with a potent bacteriostatic agent that inhibits bacterial growth.
  • Secure Online Ordering: They provides a secure online platform for effortless bacteriostatic water purchases.

Semaglutide Dosing Guide | Verdict

Semaglutide has emerged as a remarkable breakthrough in the fields of weight loss and diabetes management.

Its effectiveness in facilitating significant weight reduction has positioned it as a valuable tool for countless individuals striving to achieve their weight loss goals. However, it is essential for researchers to follow proper guidelines when dosing Semaglutide.

Ongoing research and clinical trials continue to uncover the full potential of semaglutide, solidifying its status as a treatment option for improving overall health and well-being through weight loss.

To research the limitless potential of semaglutide and other weight loss peptides, head over to our top-rated vendor and supplier.


  1. Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21.
  2. Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev. 2019 Jun;20(6):805-815. doi: 10.1111/obr.12839. Epub 2019 Feb 15.
  3. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022 Jan;70(1):5-13. doi: 10.1136/jim-2021-001952. Epub 2021 Oct 27.
  4. FDA approves once-weekly Wegovy injection for the treatment of obesity in teens aged 12 years and older. Novo Nordisk USA. December 23, 2022. Accessed January 3, 2023.
  5. FDA. (2021). Drug Label Information: HIGHLIGHTS OF PRESCRIBING INFORMATION of RYBELSUS (semaglutide) tablets. Retrieved from
  6. FDA. (2022). Drug Label Information HIGHLIGHTS OF PRESCRIBING INFORMATION of WEGOVY (semaglutide) injection. Retrieved from
  7. Sorli C, Harashima S, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial. Lancet Diabetes Endocrinol (2017) 5:251–60. doi: 10.1016/S2213-8587(17)30013-X
  8. Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients With Type 2 Diabetes (SUSTAIN 2): A 56-Week, Double-Blind, Phase 3a, Randomised Trial. Lancet Diabetes Endocrinol (2017) 5:341–54.
  9. Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, et al. Safety and Efficacy of Semaglutide Once Weekly vs Sitagliptin Once Daily, Both as Monotherapy in JApanese People With Type 2 Diabetes. Diabetes Obes Metab (2018) 20:378–88. doi: 10.1111/dom.13082
  10. Kaku K, Yamada Y, Watada H, Abiko A, Nishida T, Zacho J, et al. Safety and Efficacy of Once-Weekly Semaglutide vs Additional Oral Antidiabetic Drugs in Japanese People With Inadequately Controlled Type 2 Diabetes: A Randomized Trial. Diabetes Obes Metab (2018) 20:1202–12. doi: 10.1111/dom.13218
  11. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563
  12. Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Tria. Diabetes Care (2018) 41:258–66. doi: 10.2337/dc17-0417
  13. Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrèges JP, Lindegaard ML, Jensen CB, Atkin SL A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care. 2016 Feb;39(2):231-41.
  14. Meier JJ. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Front Endocrinol (Lausanne). 2021 Jun 25;12:645617. doi: 10.3389/fendo.2021.645617.
  15. Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes Obes Metab. 2020 Aug;22(8):1263-1277.
  16. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619.

Scientifically Fact Checked by:

David Warmflash, M.D.

Table of Contents
    Add a header to begin generating the table of contents